Trial (reference) | No. of patients randomized RT / no RT (analyzed) | RT prescription* | Biologically effective dose (Gy10) | Compliance with RT†0 <1 >1 | Surgical delay after RT (days) | Median follow-up (months) | Study quality score‡ |
---|---|---|---|---|---|---|---|
Yale [16] | 15 (15) / 16 (16) | 45 in 25 (31) 2 fields, G | 53.1 | - 7% - | 2–42 | >60 | 0.29 |
Toronto [17] | 60 (60) / 65 (65) | 5 in 1 (1) 2 fields, P | 7.5 | - - - | 0 | 72 | 0.55 |
MRC-I [18] | 549 (549) / 275 (275) | 5 in 1 (1) or 20 in10 (14) 2 fields, G | 7.5 or 19.8 | 2% 6% - | <7 | >60 | 0.66 |
VASOG-II [19] | 180 (180) / 181 (181) | 31.5 in 18 (24) 2 fields, G | 26.8 | 7% 11% 4% | ~40 | 60 | 0.70 |
Norway [20] | 159 (155) / 150 (145) | 31.5 in 18 (24) 2 fields, G | 26.8 | 1% - - | <21 | 54 | 0.80 |
EORTC [21] | 236 (231) / 230 (228) | 34.5 in 15 (19) 2 fields, G | 35.2 | 1% - - | 1–69 | >72 | 0.67 |
Brazil [22] | 34 (34) / 34 (34) | 40 in 20 (25) 2 fields, P | 35.4 | - - - | 7 | 120 | 0.48 |
Hungary [23] | 171 (171) / 165 (165) | 40 in 20 (26) or 50 in 25 (33) 2 fields, P | 35.4 or 43.2 | - - - | 42 | >60 | 0.44 |
ICRF-UK [24] | 228 (228) / 239 (239) | 15 in 3 (5–7) 2 fields, P | 22.5 | - 10% - | <2 | 60 | 0.64 |
Stockholm-I [25] | 424 (424) / 425 (425) | 25 in 5 (5–7) 2 fields, G | 37.5 | - 12% - | <7 | 107 | 0.74 |
MRC-II [26] | 139 (139) / 140 (140) | 40 in 20 (28) 2 fields, P | 35.4 | 1% 5% 4% | <7 | >60 | 0.83 |
NW-UK [27] | 143 (143) / 141 (141) | 20 in 4 (4) 3 field, P | 30.0 | - 1% 3% | <7 | 96 | 0.57 |
Sweden [28] | 583 (573) / 585 (574) | 25 in 5 (5) 3–4 fields, P | 37.5 | 3% 1%§ - | <7 | >60 | 0.82 |
Stockholm-II [29] | 272 (272) / 285 (285) | 25 in 5 (5–7) 4 fields, P | 37.7 | -------5%------ | <7 | 50 | 0.88 |
Dutch [38] | 924 (908) / 937 (897) | 25 in 5 (5) 4 fields, P | 37.5 | 3% 2% ? | <7 | 24.9 | 0.81 |